Objective: To determine the utilization of predonated autologous blood in patients treated with anterior cervical corpectomy and fusion (ACCF).
Methods: Retrospective chart review of 154 patients who underwent 1, 2, or 3-level ACCF over a 6-year period was performed. Variables collected included patterns of autologous and allogenic blood use, blood loss, and hematocrit at admission and discharge from the hospital.
Results: For 1-level ACCF, only 16.7% of the predonated autologous blood was used. As expected, use of predonated autologous blood increased with the number of corpectomy levels: Patients with 2 and 3-level ACCF used 29.0% and 53.4% of the predonated blood, respectively. The use of autologous blood significantly reduced the need for allogenic blood transfusion for 2 and 3-level ACCF.
Conclusions: Autologous blood was used efficiently in 3-level ACCF, and predonation is associated with decreased allogeneic blood transfusion requirement in 2 and 3-level ACCF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/BSD.0b013e31802d8383 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of adjunct bezlotoxumab for preventing infection recurrence in patients post - hematopoietic stem cell transplantation.
J Oncol Pharm Pract
January 2025
Department of Pharmacy, SSM Health Saint Louis University Hospital, Saint Louis, MO, USA.
Background: Patients post hematopoietic stem cell transplant (HSCT) are highly susceptible to infection (CDI). Exposure to antibiotic treatment, chemotherapeutic disruption to bacterial microbiome, immunosuppressive therapy, and prolonged hospitalizations synergistically contribute to the risk of CDI and its recurrence. The purpose of this study is to assess if the adjunctive administration of bezlotoxumab decreases the rate of recurrent CDI in patients post-HSCT.
View Article and Find Full Text PDFClinical significance of retrograde inferior parathyroid protection technique based on thymus preservation in thyroid surgery.
BMC Endocr Disord
January 2025
The Department of Thyroid Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, 350001, China.
Background: The importance of parathyroid gland preservation in thyroid surgery has been well recognized; however, the rapid identification of the parathyroid gland, particularly the inferior parathyroid gland (IPG), remains challenging. This study aimed to evaluate the effectiveness of retrograde inferior parathyroid protection technique (RIPPT) based on thymus preservation.
Methods: A total of 236 patients were enrolled in this study between August 2019 and December 2020.
[Clinical characteristics and prognosis of type 1 infratentorial superficial siderosis].
Zhonghua Yi Xue Za Zhi
February 2025
Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China.
A total of 7 patients with type 1 infratentorial superficial siderosis(iSS-1)in Memory Clinic at Huashan Hospital, Fudan University from March 2019 to March 2023 were respectively collected to analyze the clinical characteristics and treatment, and followed up for 12 months. There were 7 patients, 2 males and 5 females, aged 56 (49-60) years. The 4 patients who underwent cognitive assessment had varying degree of cognitive impairment, with 2 patients exhibiting severe executive function impairment.
View Article and Find Full Text PDFCD19 CAR-T With Axicabtagene Ciloleucel in R/R Large B-Cell Lymphoma With/Without Prior Autologous Stem Cell Transplant.
Clin Lymphoma Myeloma Leuk
January 2025
Transplantation & Cellular Therapy Program, Division of Hematology/Oncology, Department of Internal Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, University of Maryland School of Medicine, Baltimore, MD.
Background: Anti-CD19 CAR-T therapy has been a breakthrough in treatment of primary refractory or relapsed large B-cell lymphoma (r/r LBCL) and is poised to supplant previous second line of high dose chemotherapy and autologous stem cell transplantation (HDT/ASCT). However, in clinical practice, high risk patients with chemoimmunotherapy sensitive disease continue to receive salvage chemoimmunotherapy or cannot access CAR-T in a timely manner and thus may still proceed to HDT/ASCT. Little is known about clinical outcomes of CAR-T in patients who receive HDT/ASCT compared to those who are transplant-naïve.
View Article and Find Full Text PDFISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells.
Cytotherapy
January 2025
Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!